JonesResearch analyst Justin Walsh downgraded Vor Bio (VOR) to Hold from Buy without a price target after the company announced it is exploring a range of strategic alternatives. The firm cites the wind down of Vor’s clinical and manufacturing operations and its 95% workforce reduction for the downgrade. The company’s planned and ongoing clinical trials as well as manufacturing operations have been suspended immediately, JonesResearch points out.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR: